Lifeboat Foundation

Cellular Aquaculture — Feed The World and Save the Oceans — Lou Cooperhouse, President & CEO, of BlueNalu, joins me on ideaXme (https://radioideaxme.com/) to discuss his company’s technologies to provide the world with healthy and safe cell-based seafood products, and support the sustainability and diversity of our oceans — #Ideaxme #StemCells #Aquaculture #Oceans #Fish #Sushi #Poke #Ceviche #SustainableDevelopment #Agriculture #Health #Wellness #RegenerativeMedicine #Biotech #Longevity #Aging #IraPastor #Bioquark #Regenerage ideaXme BlueNalu Rutgers University Rich Products Sumitomo Chemical: Group Companies of the Americas KBW Investments.

Ira Pastor, ideaXme life sciences ambassador and founder of Bioquark, interviews Lou Cooperhouse, President and CEO of BlueNalu.

Continue reading “Feeding the World with Cellular Aquaculture: Food Security and Sustainability” »

Deploying “AI for Good” In The Life Sciences — Tom Lawry, National Director for Artificial Intelligence, Health & Life Sciences, Microsoft, joins me on ideaXme to discuss how they are deploying artificial intelligence “at scale”, across the major organizations responsible for delivery quality, next generation healthcare to millions of patients and customers — #Ideaxme #Microsoft #ArtificialIntelligence #MachineLearning #DeepLearning #Health #Healthcare #Wellness #Medicine #Pharmacy #Hospitals #Nursing #Insurance #Diagnostics #Data #Moonshots #Biotechnology #Longevity #LifeExtension #Aging #IraPastor #Bioquark #Regenerage

Ira Pastor, ideaXme life sciences ambassador, interviews Tom Lawry, National Director for Artificial Intelligence — Health & Life Sciences at Microsoft.

Continue reading “Tom Lawry Talks of Machine Learning and Microsoft AI For Good in Healthcare” »

Worldwide, 800,000 people die annually due to suicide (1 every 40 seconds) — There are more than twice as many suicides as homicides — Suicide is now the 10th leading cause of death in the US, and the 2nd leading cause of death among individuals between ages of 10 and 34 — Dr. Christine Moutier, M.D., Chief Medical Officer, American Foundation for Suicide Prevention, joins me on ideaXme to discuss her organization’s work in suicide prevention science and impacting these disturbing trends — #Ideaxme #Suicide #Depression #MentalHealth #Psychiatry #Anxiety #Stress #Trauma #Coronavirus #Burnout #WellBeing #Resilience #Health #Wellness #Longevity #Aging #IraPastor #Bioquark #Regenerage National Institute of Mental Health National Academy of Medicine.

Ira Pastor, ideaXme life sciences ambassador and founder of Bioquark, interviews Dr. Christine Moutier, MD, Chief Medical Officer, at the American Foundation for Suicide Prevention (AFSP).

Continue reading “Dr Christine Moutier talks of Mental Health Awareness, Suicide Prevention and Building Resilience” »

The masks could screen for the coronavirus at airports, hospitals, and offices. They could also double as a diagnostic test.

Sensors produce a fluorescent light when an infected person breathes, coughs, or sneezes into the mask.

WOW! A reduction in air pollution means residents in Nepal can see Mount Everest from over 120 miles away for the first time in decades. https://bit.ly/3bPjlNt

An incredible photo shows Mount Everest visible for the first time in decades from the Nepalese city of Kathmandu.

A coronavirus lockdown-related reduction in air pollution has made the famous visible from the city 124 miles away, according to the Nepali Times. The photo was taken by Abhushan Gautam from the Kathmandu Valley on May 10.

Continue reading “Mount Everest visible from over 120 miles away due to decrease in pollution” »

Check out Megaprojects: https://www.youtube.com/channel/UC0woBco6Dgcxt0h8SwyyOmw

→Subscribe for new videos every day!

Continue reading “10 Facts That Prove Viruses are the Weirdest Life Forms” »

Cross-posted from U.S. Food and Drug Administration

[On July 2, 2020], the U.S. Food and Drug Administration approved Rukobia (fostemsavir), a new type of antiretroviral medication for adults living with HIV who have tried multiple HIV medications and whose HIV infection cannot be successfully treated with other therapies because of resistance, intolerance or safety considerations.

“This approval marks a new class of antiretroviral medications that may benefit patients who have run out of HIV treatment options,” said Jeff Murray, M.D., deputy director of the Division of Antivirals in the FDA’s Center for Drug Evaluation and Research. “The availability of new classes of antiretroviral drugs is critical for heavily treatment-experienced patients living with multidrug resistant HIV infection—helping people living with hard-to-treat HIV who are at greater risk for HIV-related complications, to potentially live longer, healthier lives.”

Bioengineering.

There is currently no vaccine or cure towards COVID-19. It is predicted the development of a safe and effective vaccine to prevent COVID-19 will take 12 to 18 months, by which time hundreds of thousands to millions of people may have been infected. With a rapidly growing number of cases and deaths around the world, this emerging threat requires a nimble and targeted means of protection.

Could CRISPR be the next virus killer? To address this global pandemic challenge, we are developing a genetic vaccine that can be used rapidly in healthy and patients to greatly reduce the coronavirus spreading. We developed a safe and effective CRISPR system to precisely target, cut and destroy COVID-19 virus and its genome, which stops coronavirus from infecting the human lung.

Continue reading “New genetic method of using CRISPR to eliminate COVID-19 virus genomes in cells” »

Findings In this bayesian randomized clinical trial that included 403 patients and was stopped early after results from another trial were released, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority, respectively, with regard to the odds of improvement in organ support–free days within 21 days.

Objective To determine whether hydrocortisone improves outcome for patients with severe COVID-19.

Design, Setting, and Participants An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020.

Continue reading “Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial” »